Open AccessLong-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies
Author(s) -
Mark C. Genovese,
Patrick Durez,
Roy Fleischmann,
Yoshiya Tanaka,
Daniel E. Fürst,
Hisashi Yamanaka,
Elena Korneva,
Igor Vasyutin,
Tsutomu Takeuchi
Publication year - 2021
Publication title -
european journal of rheumatology
Language(s) - English
Resource type - Journals
eISSN - 2147-9720
pISSN - 2148-4279
DOI - 10.5152/eurjrheum.2021.19207
Subject(s) - medicine , adverse effect , rheumatoid arthritis , tocilizumab , methotrexate , placebo , gastroenterology , surgery , pathology , alternative medicine
This study aimed to evaluate the long-term safety and efficacy of olokizumab (OKZ), an anti-interleukin (IL)-6 monoclonal antibody, in patients with rheumatoid arthritis (RA) and inadequate response to tumor necrosis factor-alpha inhibitors.